logowebretinalogowebretinalogowebretinalogowebretina
  • Home
  • About us
  • Solution
  • Library
  • News
  • Careers
  • Contact
Corify participates in the EIT-Health AFFINE project
15 April, 2019
Corify selected as the most promising start-up in the I Life Sciences investor capital forum
27 February, 2020
17 July, 2019
July 17, 2019:

Corify Care: jumping from high impact journals to improving patient’s quality of life


Developing new technologies to help solve the most pressing issues in healthcare is the number one goal for any biomedical engineer, and Andreu Climent is no exception. He is the CEO of the Madrid-based medtech start-up, Corify Care, a spin-off from the Hospital Gregorio Marañon, and a former CaixaImpulse project. Now, he is well on his way to reaching this goal, with his company’s novel technology on track to enter the market by 2023.
Corify Care’s innovation aids the classification of disease severity for patients suffering from atrial fibrillation (AF). This serious heart condition can lead to a number of devastating consequences for patients, such as dramatically reducing life expectancy and increasing the risk of embolic stroke, heart failure and dementia. Until now, a one-size-fits-all approach has been applied to AF therapies, meaning that patients with differing variations of the disease may end up receiving treatments that are either too aggressive or ineffective for their condition.
Andreu Climent, CEO of Corify Care

Andreu Climent, CEO of Corify Care

Andreu Climent identified this problem while working in the cardiology department of several different hospitals. “In all of the hospitals I’ve worked, clinicians have had common complaints regarding the inefficient flowchart of treatment of AF patients.” In order to address this, Corify Care’s novel technology classifies disease severity, thus facilitating the process of prescribing the appropriate treatment. For example, many patients who were not considered for aggressive ablation therapies, currently the most effective available, will now benefit from these treatments if Corify Care’s technology identifies their AF as simple.
Andreu describes CaixaImpulse 2017 as a fundamental step in the development of the project. The training received and contacts made through the programme enabled Corify Care to advance on the path towards commercialisation – which they now envision reaching by 2023.
He says that for him, the most important gain from CaixaImpulse was the change in perception. “Thanks to CaixaImpulse I was finally able to understand the process of jumping from a high impact journal to improving the quality of life of patients. It enabled us to predict the different death valleys and meet the people that could help us overcome them,” he comments. It has even changed his approach to basic research: “Now, even when we are in the earliest stages of a new line of research, we are already considering the questions that investors and regulatory would ask, and how we can adjust the experimental design to reduce the time to market.”
Corify is currently treating patients under proof of concept clinical trials – and highly promising preliminary results are already being reported. To date, more than 150 patients at Madrid’s Hospital Gregorio Marañon have been characterised using Corify technology. Andreu predicts that this technology will be helping millions of patients within the decade.
What’s next for Corify? “Thanks to the support of private investors, we are at the stage of jumping from prototype to a certifiable product.” To bolster this final developmental step, they are focusing on expanding their team, incorporating experts from such diverse backgrounds as investment, management, production, regulation and market access.

Related posts

10 December, 2020

Corify Care’s CEO, Andreu Climent, winner of the 2020 European Institute of Innovation and Technology Award


Read more
3 December, 2020

CORIFY CARE, awarded of the Quality Innovation Award (QIA) for its ACORYS innovation, will represent Spain in the international phase of the QIAs.


Read more
13 November, 2020

Corify Care participated in the CEI Satellite Meeting CinC 2020: Challenges in the Daily Application of ECGI


Read more

Footer webpage

corify_white

Supported by:

healthcare

euhealth

Sello PYME INNOVADORA 15/07/2023
PYME INNOVADORA
Válido hasta el 15 de julio de 2023
escudo de MEIC 15/07/2023

footer para corify

News

  • Corify Care’s CEO, Andreu Climent, winner of the 2020 European Institute of Innovation and Technology Award
    10 December, 2020
CALL US

+34 910 888 183

OR WRITE

corify@corify.es

Twitter

Retweet on TwitterCorify Care Retweeted
Centros Excelencia@CentrosCex·
12 Apr

@corifyAF, empresa ganadora de los #PremiosQIA en la categoría #Innovación en el #SectorSanitario, por #ACORYS, solución no invasiva para el diagnóstico de enfermedades ... cardiovasculares basándose en la combinación de #ECGI, #3D e #InteligenciaArtificial.
https://youtu.be/xxKIIn7uAnM

Reply on Twitter 1381487431149572097Retweet on Twitter 13814874311495720971Like on Twitter 13814874311495720971Twitter 1381487431149572097
2020 Corify. All Rights Reserved. Privacy